These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 9617599

  • 21. Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension.
    Persson B, Widgren BR, Fox A, Stimpel M.
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):73-8. PubMed ID: 7564369
    [Abstract] [Full Text] [Related]

  • 22. ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.
    Pines A, Fisman EZ.
    Am J Cardiovasc Drugs; 2003 Jul; 3(5):351-60. PubMed ID: 14728069
    [Abstract] [Full Text] [Related]

  • 23. [Angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension. Possibilities of moexipril in the treatment of postmenopausal women].
    Ostroumova OD, Paukov SV, Frolova LI.
    Kardiologiia; 2006 Jul; 46(11):92-8. PubMed ID: 17159885
    [Abstract] [Full Text] [Related]

  • 24. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension.
    Wiseman LR, McTavish D.
    Drugs; 1994 Jul; 48(1):71-90. PubMed ID: 7525196
    [Abstract] [Full Text] [Related]

  • 25. Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor moexipril, 17beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats.
    Stimpel M, Jee WS, Ma Y, Yamamoto N, Chen Y.
    J Hypertens; 1995 Dec; 13(12 Pt 2):1852-6. PubMed ID: 8903666
    [Abstract] [Full Text] [Related]

  • 26. Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats.
    Ma YF, Stimpel M, Liang H, Pun S, Jee WS.
    J Endocrinol; 1997 Sep; 154(3):467-74. PubMed ID: 9379124
    [Abstract] [Full Text] [Related]

  • 27. Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide.
    Hutt V, Michaelis K, Verbesselt R, De Schepper PJ, Salomon P, Bonn R, Cawello W, Angehrn JC.
    Eur J Clin Pharmacol; 1996 Sep; 51(3-4):339-44. PubMed ID: 9010710
    [Abstract] [Full Text] [Related]

  • 28. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
    Edling O, Bao G, Feelisch M, Unger T, Gohlke P.
    J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
    [Abstract] [Full Text] [Related]

  • 29. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.
    Culy CR, Jarvis B.
    Drugs; 2002 Nov; 62(2):339-85. PubMed ID: 11817979
    [Abstract] [Full Text] [Related]

  • 30. Moexipril: another ACE inhibitor for hypertension.
    Med Lett Drugs Ther; 1995 Sep 01; 37(956):75-6. PubMed ID: 7637658
    [No Abstract] [Full Text] [Related]

  • 31. Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril.
    Blacher J, Raison J, Amah G, Schiemann AL, Stimpel M, Safar ME.
    Cardiovasc Drugs Ther; 1998 Sep 01; 12(4):409-14. PubMed ID: 9825188
    [Abstract] [Full Text] [Related]

  • 32. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
    Muijsers RB, Curran MP, Perry CM.
    Drugs; 2002 Sep 01; 62(17):2539-67. PubMed ID: 12421112
    [Abstract] [Full Text] [Related]

  • 33. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
    Cawello W, Boekens H, Waitzinger J, Miller U.
    Int J Clin Pharmacol Ther; 2002 Jan 01; 40(1):9-17. PubMed ID: 11837383
    [Abstract] [Full Text] [Related]

  • 34. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
    Plosker GL, Sorkin EM.
    Drugs; 1994 Aug 01; 48(2):227-52. PubMed ID: 7527326
    [Abstract] [Full Text] [Related]

  • 35. Regression of left ventricular hypertrophy with moexipril, an angiotensin-converting enzyme inhibitor, in hypertensive patients.
    Sayegh F, Topouchian J, Hlawaty M, Olzewska M, Asmar R.
    Am J Ther; 2005 Aug 01; 12(1):3-8. PubMed ID: 15662286
    [Abstract] [Full Text] [Related]

  • 36. Perindopril: an updated review of its use in hypertension.
    Hurst M, Jarvis B.
    Drugs; 2001 Aug 01; 61(6):867-96. PubMed ID: 11398915
    [Abstract] [Full Text] [Related]

  • 37. Speed and duration of dose titration with the angiotensin converting enzyme inhibitor quinapril: relationship with efficacy in patients with moderate hypertension.
    Weir MR.
    J Hum Hypertens; 1994 Sep 01; 8(9):725-30. PubMed ID: 7807504
    [Abstract] [Full Text] [Related]

  • 38. MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial.
    Spinar J, Vítovec J, MORE Investigators.
    Int J Cardiol; 2005 Apr 20; 100(2):199-206. PubMed ID: 15823625
    [Abstract] [Full Text] [Related]

  • 39. Evidence for site-specific absorption of a novel ACE inhibitor.
    Grass GM, Morehead WT.
    Pharm Res; 1989 Sep 20; 6(9):759-65. PubMed ID: 2554270
    [Abstract] [Full Text] [Related]

  • 40. Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension.
    Dickstein K, Aarsland T, Ferrari P, Todd M, Stimpel M.
    J Cardiovasc Pharmacol; 1994 Aug 20; 24(2):247-55. PubMed ID: 7526056
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.